117976-90-6 Usage
Description
Rebeprazole sodium, also known as Rabeprazole sodium, is a proton pump inhibitor that selectively and irreversibly inhibits the gastric H+/K+ ATPase. It is a white crystalline solid that is very soluble in water and methanol, freely soluble in ethanol, chloroform, and ethyl acetate, and insoluble in ether and hexane. Rebeprazole sodium is a weak base (pyridine N, pKa 4.53) and a weak acid (benzimidazole N-H, pKa 0.62), facilitating sodium salt formation. It is formulated as enteric-coated, delayed-release tablets to allow the drug to pass through the stomach relatively intact.
Used in Pharmaceutical Industry:
Rebeprazole sodium is used as a gastric proton pump inhibitor for the treatment of various gastrointestinal conditions. It is a more potent inhibitor of gastric H+/K+-adenosine triphosphate (ATPase) compared to other proton pump inhibitors, such as omeprazole, lansoprazole, and pantoprazole. It has a faster onset of action and can be activated over a greater pH range than other proton pump inhibitors.
Rebeprazole sodium is used as an anthelmintic, antiseptic, and expectorant for the treatment of various gastrointestinal disorders.
Used in Antimicrobial Applications:
Rebeprazole sodium is used as an antibacterial and antifungal agent, effective against gram-positive and gram-negative bacteria, yeast, and fungi. It has shown antibacterial activity against Helicobacter pylori, with a MIC90 of 1.56 μg/ml.
Used in Gastrointestinal Treatment:
Rebeprazole sodium is used as a treatment for gastric ulcers, peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. In clinical studies, 10 and 20 mg rabeprazole sodium once-daily significantly inhibited basal and stimulated acid output.
Rebeprazole sodium is used in formulations containing the drug for the treatment of ulcers, pathological hypersecretory conditions, and gastroesophageal reflux disease (GERD).
Anti-ulcer drug
Rabeprazole sodium is a anti-ulcer disease drug belonging to proton pump inhibitor and is the sodium salt form of Rabeprazole. The Japanese company Eisai had successfully developed it for the first time with the trade name being “Bolite”. The function of the proton pump inhibitors is reducing the gastric acid secretion so that the lesion site can be stable in order to achieving the effect of curing gastric and duodenal ulcers and stomach-esophageal reflux disease. Clinically it is majorly used for the treatment of acid-related diseases such as stomach and duodenal ulcers, peptic ulcer, gastroesophageal reflux disease and zollinger-ellison syndrome.
Rabeprazole is a kind of benzimidazole-substituted compounds. It inhibits the secretion of gastric acid through forming bond with the cytoplasmic proton pump in the gastric cavity wall. This product can specifically inhibit the effect of the adenosine triphosphatase that is the key enzyme during the production of stomach acid. It has inhibitory effect on both basal gastric acid and the gastric acid secretion caused by the stimulation.
Rabeprazole is white-yellowish-white powder with no odor and a molecular weight being 381.43. This product is highly soluble in water or methanol, also soluble in ethanol or ethyl acetate but almost insoluble in ether or ethane. This product does not exhibit optical activity, has hygroscopic effect. Its melting point is 225 ℃ and its partition coefficient at water/octane system of pH 7.0 is about 214. This product is light yellow film-coated tablets (enteric-coated tablets).
Adverse reactions and precautions: gastric cancer should be excluded after use of the drug. Adverse reactions include allergic reactions, palpitations, constipation, diarrhea, headache, edema, leukopenia, AST, ALT, total bilirubin and proteinuria. The combination of Rabeprazole sodium and digoxin can cause increased digoxin concentration. It can’t be taken simultaneously with antacids. Patients of history of drug allergy, cirrhosis, the elderly, pregnant and lactating women, children should take with caution.
The above information is edited by the lookchem of Dai Xiongfeng.
Originator
Eisai (Japan)
Biochem/physiol Actions
Rabeprazole sodium is gastric proton pump inhibitor. It suppresses the production of acid in the stomach by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Rabeprazole sodium has been used clinically to treat acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevent gastroinetestinal bleeds associated with NSAID use.
Clinical Use
Gastric acid suppression
Drug interactions
Potentially hazardous interactions with other drugs
Antifungals: absorption of itraconazole and
ketoconazole reduced; avoid with posaconazole.
Antivirals: concentration of atazanavir and rilpivirine
reduced - avoid; concentration of raltegravir and
saquinavir possibly increased - avoid.
Clopidogrel: possibly reduced antiplatelet effect.
Cytotoxics: possibly reduced excretion of
methotrexate; avoid with dasatinib, erlotinib and
vandetanib; possibly reduced lapatinib absorption;
possibly reduced absorption of pazopanib.
Ulipristal: reduced contraceptive effect, avoid with
high dose ulipristal.
Metabolism
Rabeprazole is mainly metabolised via nonenzymatic
reduction and, to a lesser extent, via the cytochrome P450
isoenzymes CYP2C19 and CYP3A4. Metabolites are
excreted principally in the urine (about 90%) with the
remainder in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 117976-90-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,7,9,7 and 6 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 117976-90:
(8*1)+(7*1)+(6*7)+(5*9)+(4*7)+(3*6)+(2*9)+(1*0)=166
166 % 10 = 6
So 117976-90-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1/rC18H20N3NaO3S/c1-13-15(19-9-8-17(13)25-11-5-10-24-2)12-26(23)18-20-14-6-3-4-7-16(14)21(18)22/h3-4,6-9H,5,10-12H2,1-2H3
117976-90-6Relevant articles and documents
A right-handed thunder beira zuozuo sodium hydrate crystal form and its preparation method
-
Paragraph 0054-0055, (2019/01/16)
The invention relates to a novel crystal form of rabeprazole sodium aquo-complex and a preparation method of the novel crystal form. The novel crystal form is called the Z-type crystal. The Z-type crystal of the rabeprazole sodium aquo-complex is characterized in that in the X-ray powder diffraction pattern expressed by Cu-K alpha radiation and a 2theta+/-0.2DEG diffraction angle, the Z-type crystal has characteristic diffraction peaks at 9.3, 10.7, 18.2, 19.6, 21.2, 23.0, 27.2 and 29.9.
Method for preparing optically-pure Rabeprazole
-
Paragraph 0077; 0078; 0079; 0080, (2017/08/28)
The invention discloses a method for preparing optically-pure Rabeprazole. The method is used for preparing a chiral 2-[[4-(3-methoxypropoxy)-3-methylpyrid-2-yl]methylsulfinyl]-1H-benzimidazole compound (Rabeprazole), which is present in a single-enantiomer form or rich-enantiomer form, in an enantioselective manner. The same effects, i.e., identical enantioselectivity and conversion ratio can be achieved through complexing a tartaric acid diamide ligand and titanium and adding an organic-base additive or not in the presence of water. The invention further provides a method for preparing a sodium salt from the obtained Rabeprazole.
A process for the preparation of sodium rebeilazole for
-
Paragraph 0021; 0022, (2016/10/07)
The invention provides a preparation method of sodium rabeprazole. The preparation method comprises the following four steps of (1) adding rabeprazole into a mixed solvent of 2-fluoro-3-chloro-5-trifluoromethyl pyridines and ethanol, and regulating the temperature at 35-40 DEG C; (2) adding anhydrous sodium carbonate and anhydrous sodium sulfate into a reaction solution until the pH value of the reaction solution is 8.0-10.0, keeping the temperature at 35-40 DEG C, and reacting for 2h under stirring; (3) continuing to add n-hexane, and reacting at the temperature of 35-40 DEG C for 2h under stirring; and (4) carrying out solid-liquid separation, and drying at reduced pressure to obtain sodium rabeprazole. The method is simple in process, and sodium rabeprazole is high in purity, low in water content and good in stability.